UPDATE 1-Archimed to take Esperion Therapeutics private in $1.1 billion deal

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

ESPR

0.00

Adds share movement in paragraph 1, details in paragraphs 2-5

May 1 (Reuters) - Investment firm Archimed will take Esperion Therapeutics ESPR.O private for up to $1.1 billion, the companies said on Friday, sending the drugmaker's shares up over 55% in premarket trading.

Under the terms of the agreement, Esperion shareholders will receive $3.16 in cash for each share, representing a premium of about 58% to the company's last closing price.

Shareholders could also receive additional contingent payments totaling up to $100 million if Esperion meets certain sales targets in the coming years, the companies said.

As of last close, Esperion had a market value of $514.81 million, according to data compiled by LSEG.

The deal is expected to close in the third quarter of 2026.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.